Stevens Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Stevens Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,935	Closed	-$295K	–	680
2019 Q3	$295K	Buy	+1,935	New	+$317K	0.03%	458
2019 Q2	–	Sell	-3,383	Closed	-$398K	–	711
2019 Q1	$398K	Buy	+3,383	New	+$341K	0.02%	525
2017 Q3	–	Sell	-3,813	Closed	-$292K	–	928
2017 Q2	$292K	Buy	+3,813	New	+$321K	0.01%	687
2016 Q2	–	Sell	-8,793	Closed	-$368K	–	981
2016 Q1	$368K	Buy	+8,793	New	+$408K	0.01%	637

Other funds holding LKFT

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

Stevens Capital Management's LKFT Position: Q4 2019 in Review

Stevens Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2019, closing a stake of 1,935 shares — an estimated $295K sold.

Stevens Capital Management first reported a position in LKFT in Q1 2016 and held it in 4 quarters. The position peaked at $398K in Q1 2019. 137 funds tracked by Wall St. Rank hold LKFT as of Q4 2019.

Stevens Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2019 after selling out during the quarter.
Stevens Capital Management sold 1,935 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2019, an estimated $295K.
Stevens Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2016 and held it in 4 quarters.
Stevens Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $398K in Q1 2019.
137 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2019.

Based on Stevens Capital Management's 13F filing for Q4 2019, filed 6 Feb 2020.